Risperidone in the treatment of mixed state bipolar patients: results from a 24-week, multicenter, open-label study in Korea.

Abstract

AIMS:

The goal of the present study was to evaluate the efficacy of risperidone combined with mood stabilizers for treating bipolar mixed state.

METHODS:

The present study was a 24-week, open-label, combination, prospective investigation of the efficacy of risperidone in combination with mood stabilizers. Risperidone (1-6 mg/day) was given in combination with mood stabilizers in flexible doses according to clinical response and tolerability for 114 patients in mixed or manic episode.

RESULTS:

Forty-four patients met our criteria for mixed state bipolar disorder and 70 met the criteria for pure mania. Mean age for the subjects was 39.0 +/- 11.0 years and 55.3% were female. The combination of risperidone with mood stabilizers significantly improved the scores on the Young Mania Rating Scale (YMRS), 17-item Hamilton Rating Scale for Depression (HAMD), 18-item Brief Psychiatric Rating Scale (BPRS), Global Assessment Scale (GAS), and Clinical Global Impression Scale for use in bipolar illness Severity (CGI-BP) at 24 weeks (P < 0.0001). Analysis of the YMRS, BPRS, GAS, and CGI-BP scores showed significant improvement in both the manic and mixed groups. The rate of response in YMRS scores was 84.2% (n = 96) and the rate of YMRS remission was 77.2% (n = 88) at week 24 in the total population. Seventy-four patients met both YMRS < or = 12 and HAMD < or = 7 at week 24 (64.9%). Risperidone was well tolerated, and adverse events were mostly mild.

CONCLUSION:

The combination of risperidone with mood stabilizers was an effective and safe treatment for manic symptoms and coexisting depressive symptoms of bipolar disorder.

• Authors: Young Sup Woo, Won-Myong Bahk, Duk-In Jon, Sang-Keun Chung, Sang-Yeol Lee, Yong Min Ahn, Chi-Un Pae, Hyun-Sang Cho, Jeong-Gee Kim, Tae-Yeon Hwang, Hong-Seok Lee, Kyung Joon Min, Kyung-Uk Lee, Bo-Hyun Yoon
• Journal: Psychiatry and clinical neurosciences (Psychiatry Clin Neurosci) Vol. 64 Issue 1 Pg. 28-37 (Feb 2010) ISSN: 1440-1819 [Electronic] Australia
• PMID: 19895394 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)

Chemical References

• Antimanic Agents
• Antipsychotic Agents
• Risperidone

Topics

• Adult
• Antimanic Agents (therapeutic use)
• Antipsychotic Agents (administration & dosage, adverse effects, therapeutic use)
• Bipolar Disorder (drug therapy, psychology)
• Drug Therapy, Combination
• Female
• Humans
• Male
• Middle Aged
• Prospective Studies
• Psychiatric Status Rating Scales
• Risperidone (administration & dosage, adverse effects, therapeutic use)
• Treatment Outcome